NRXP
NRx Pharmaceuticals, Inc.Healthcare · $116M market cap
Verdict
We can't put a fair value on NRXP right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.
Business quality
2 of 5 clear the 10% bar. What are the Big Five?
Follow NRXP
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Jul 28, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Questions about NRXP
Are insiders buying NRXP?
Since Jul 28, 2026: no open-market purchases and 2 other filings (stock awards, tax withholding and similar).
How can I check NRXP's value myself?
Use the free Sticker Price calculator, already filled with NRXP's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 4, 2026. How the Payback Price works